DenovoSkin (EHSG-KF) Emerging Drug Insight

“DenovoSkin (EHSG-KF) Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about DenovoSkin (EHSG-KF) for Burns in the seven major markets. A detailed picture of the DenovoSkin (EHSG-KF) for Burns in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the DenovoSkin (EHSG-KF) for Burns. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DenovoSkin (EHSG-KF) market forecast analysis for Burns in the 7MM descriptive analysis such as SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Burns.

Drug Summary

DenovoSkin, being developed by CUTISS AG and others, is bio-engineered in large quantities (>1:100) with a thick, double layer, robust structure. DenovoSkin is a patented, personalized, autologous bio-engineered human skin graft classified as an Advanced Therapy Medical Product (ATMP). It is engineered in large quantities, starting off from a stamp-sized skin biopsy of the patient, thus solving the donor site shortage issue. Moreover, because of its dermo-epidermal structure, denovoSkin leads to minimal scarring after transplantation. DenovoSkin is also granted orphan drug designation by the Swissmedic, EMA, and FDA.

To bio-engineer denovoSkin, the patient’s epidermal and dermal cells are isolated in the GMP facility from a thin, small biopsy. The cells are expanded in vitro in 2D, and thereafter used in combination with a compressed hydrogel to create a personalized dermo-epidermal 3D skin graft, then transplanted on the patient’s wound. The current manual process takes about 3–4 weeks. Because of its intrinsic characteristics, denovoSkin is expected to be mechanically stable and result in a minimally scarring outcome after transplantation onto the patient’s wounds.

DenovoSkin has successfully completed Phase I in pediatric patients. Phase II clinical trials are now underway in Europe and Switzerland. The company is also working on the scale-up of the production process through automation. It is currently being tested in three European multi-centric Phase II/III efficacy clinical studies (NCT03227146 and NCT03229564). Both acute (burn) and elective patients (scar reconstruction, plastic surgery, etc.) are enrolled in the current studies. Burn compassionate patients have also been treated with promising results.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the DenovoSkin (EHSG-KF) description, mechanism of action, dosage and administration, research and development activities in Burns.
• Elaborated details on DenovoSkin (EHSG-KF) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DenovoSkin (EHSG-KF) research and development activities in Burns across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DenovoSkin (EHSG-KF).
• The report contains forecasted sales of for Burns till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Burns.
• The report also features the SWOT analysis with analyst views for DenovoSkin (EHSG-KF) in Burns.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DenovoSkin (EHSG-KF) Analytical Perspective by DelveInsight

• In-depth DenovoSkin (EHSG-KF) Market Assessment

This report provides a detailed market assessment of DenovoSkin (EHSG-KF) for Burns in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• DenovoSkin (EHSG-KF) Clinical Assessment

The report provides the clinical trials information of DenovoSkin (EHSG-KF) for Burns covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Burns is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DenovoSkin (EHSG-KF) dominance.
• Other emerging products for Burns are expected to give tough market competition to DenovoSkin (EHSG-KF) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DenovoSkin (EHSG-KF) in Burns.
• Our in-depth analysis of the forecasted sales data of DenovoSkin (EHSG-KF) from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DenovoSkin (EHSG-KF) in Burns.

Key Questions

• What is the product type, route of administration and mechanism of action of DenovoSkin (EHSG-KF)?
• What is the clinical trial status of the study related to DenovoSkin (EHSG-KF) in Burns and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DenovoSkin (EHSG-KF) development?
• What are the key designations that have been granted to DenovoSkin (EHSG-KF) for Burns?
• What is the forecasted market scenario of DenovoSkin (EHSG-KF) for Burns?
• What are the forecasted sales of DenovoSkin (EHSG-KF) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to DenovoSkin (EHSG-KF) for Burns?
• Which are the late-stage emerging therapies under development for the treatment of Burns?